42 results about "GN - Glomerulonephritis" patented technology

Disclosed is a Chinese medicament for treating acute glomerular nephritis wherein the recipe includes astragalus root 20g, root of red rooted saliva 15g, cogongrass rhizome 40g, rhizome smilacis glabrae 100g, motherwort 20g, malt 30g, arctium fruit 10g, bletilla tuber 12g, kudzuvine root 8g, cordate houttuynia 10g, plantain seeds, polyporus umbellatus each 20g, alkanna tinctoria, eclipta, notoginseng each 30g, Achyranthes bidentatae 25g, sweet basil, ledebouriella root each 30g. The Chinese medicament has simplified recipe, easy preparing process and low price.

Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

The present invention provides a use of compounds from Antrodia camphorata in manufacturing medicaments for treating kidney diseases, wherein the compounds is represented by formula (I):

wherein R₁ is a hydrogen atom or acetyl group, R₂ is

wherein the kidney disease is glomerulosclerosis or glomerulonephritis.

The invention discloses a short peptide, a preparation method thereof, and applications of the short pepetide in diagnosis or treatment of apoA-I related diseases. The sequence of the short peptide is Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2, wherein the amino acids used are all L-amino acids. An L-4F provided by the invention has functions similar to the apoA-I. In an accelerated arteriosclerotic mice lupus model, the L-4F is capable of reducing significantly double-stranded DNA resistance and oxidized-type PL resistance of IgG, improving degrees of proteinuria, glomerulonephritis and sclerotin reduction, increasing the amount of smooth muscle cells, reducing infiltration of macrophages, and reducing the level of inflammation chemotactic factors causing atherosclerosis at the same time. Accordingly, the L-4F treatment is a protective mechanism for lupus diseases, also has certain functions for rebuilding and fixing latent patches, and has a broad application prospect and high application value. The L-4F can be used for diagnosis and treatment of the apoA-I related diseases, and has high medicinal value. The L-4F is obtained by a solid-phase synthetic method with simple operation, and therefore the L-4F has a broad market prospect.

The invention relates to a medicament for treating latent glomerulonephritis. The medicament is prepared from the following medicinal materials in parts by weight: 15 parts of aspidistra elatior, 3 parts of medicago falcate, 12 parts of common sesbania roots and leaves, 1 part of cotton eucommia, 20 parts of gurgeon stopper roots, 15 parts of clover fern, 20 parts of pteris cretica, 9 parts of needle juniper, 7 parts of stemflower brandisia, 2 parts of fungus-infected rice spikes, 20 parts of common edelweiss herb, 15 parts of caryopteris nepetaefolia, 9 parts of roots of hollyhock, 1 part of senecio nagensium, 5 parts of rigidleaf cymbidium fruits, 25 parts of wedelia chinensis, 3 parts of delavay meadowrue roots, 5 parts of swamp mahogany leaves, 12 parts of colysis elliptica, 1 part of argiope bruennichii, 1 part of teucrium viscidum, 2 parts of salvia prionitis and 15 parts of delavay greenleaves. Clinical experiments verify that the medicament can safely and effectively treat latent glomerulonephritis.

The invention belongs to the field of biological medicines, and relates to a nano vaccine of LAMP-2 epitope peptide and a preparation method of the nano vaccine. The nano vaccine comprises an effective amount of polypeptide with the amino acid sequence as shown in SEQ IN DO:1, or a polypeptide mixture with the amino acid sequence as shown in SEQ IN DO:1 and SEQ IN DO:2, the nano vaccine can be prepared through the synergistic effect of a polylactic acid-glycolic acid copolymer with the polypeptide, and the nano vaccine can be applied to preparation of a nano vaccine for anti-neutrophile granulocyte cytoplasm antibody relevancy vasculitis and anti-LAMP-2 antibody relevancy pauci-immune complex crescent glomerulonephritis. Due to adoption of the nano vaccine, spontaneous immune response of autoantigen characteristics is eliminated, and immune response to other antigens is not interfere, and a novel method is provided for treatment on anti-neutrophile granulocyte cytoplasm antibody relevancy vasculitis and anti-LAMP-2 antibody relevancy pauci-immune complex crescent glomerulonephritis.

The invention discloses a Chinese medicament for treating nephritis. The Chinese medicament is prepared from 200 to 300 grams of astragalus root, 150 to 160 grams of sophora flavescens, 100 to 300 grams of peony bark, 200 to 250 grams of zedoary, 100 to 250 grams of field thistle, 100 to 150 grams of hedyotis diffusa and 250 to 300 grams of honeysuckle. The Chinese medicament is high in stability; and through 96 cases of clinical tests of chronic nephritis patients, the Chinese medicament is exact in treatment effect, and the clinical cure rate of glomerulonephritis or anaphylactic purpura nephritis reaches 68.4 percent.

The invention relates to a medical application of caper or caper extract, and specifically provides an application of the caper or caper extract in preparing a medicine or health care product for reducing hepatotoxicity of common threewingnut root, tripterygium glycosides or triptolide, and also provides a composition and an application thereof in preparing a medicine or health care product for preventing and treating rheumatic arthritis, glomerulonephritis, nephrotic syndrome, lupus erythematosus, Sjogren's syndrome, Behcet disease, eczema, psoriasis, leprosy, scabies, stubborn dermatitis, Hashimoto's thyroiditis or tumor, wherein the composition is prepared from a component i) and a component ii), wherein the component i) is caper or caper extract; the component ii) is tripterygium glycosides or triptolide.

The present invention provides an Antrodia camphorata and Ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney function. This navel composition is constituted of water-soluble base material, plasticity-increasing base material, Antrodia camphorata extract, Ganoderma lucidum extract, and auxiliary enzyme. Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering low-dosage Antrodia camphorata and Ganoderma lucidum composition of 7 mg/day/kg to the patient for 20 days. Moreover, because the cell biological experiments have proved that the Antrodia camphorata and Ganoderma lucidum composition of the present invention possess the functionality to inhibit renal cancer cell growth, this novel composition can indeed be used with chemotherapy drugs clinically, so as to solve the issue that the chemotherapy drugs cannot effectively inhibit the renal cancer cell growth.

The invention discloses a pharmaceutical composition of dexibuprofen and its medical use. The pharmaceutical composition of dexibuprofen provided by the invention contains dexibuprofen and a natural product compound (I) with a novel structure. When dexibuprofen and compound (I) act alone, they have a therapeutic effect on glomerulonephritis; when dexibuprofen and compound (I) act in combination, the therapeutic effect is further improved, and can be developed into a drug for treating glomerulonephritis , compared with the prior art, has outstanding substantive features and remarkable progress.

A Chinese medicine for treating chronic or primary glomerular nephritis is prepared from 5 Chinese-medicinal materials including astragalus root, Tripterygium wilfordii, dogwood fruit, liquorice root, etc through decocting and/or extracting in alcohol. Its quality control method is also disclosed. Its advantages are high curative effect and no toxic by-effect.

The invention belongs to the technical field of medicines, and particularly relates to a medicine composition for treating the phlegm-damp internal-congestion type latent glomerulonephritis. The medicine composition is prepared from, by weight, 4-8 parts of ternate-leaved rabdosia, 4-8 parts of textile screw pine seeds, 4-8 parts of CerastiumrvenseL., 4-8 parts of rhizome of largeleaf curculigo, 4-8 parts of Pecteilis susannae(L.)Rafin., 4-8 parts of oyster-cap fungi, 4-8 parts of dysosma majorensis(gagnep.)ying, 4-8 parts of balanophora polyandra griff., 4-8 parts of aralia elata, 4-8 parts of rattlesnake plantain, 4-8 parts of melothria heterophylla, 4-8 parts of Crossostephium chinense (L.) Makino ex Cham.et Schltr., 4-8 parts of cortex moutan, 4-8 parts of rhizoma alismatis and 4-8 parts of liquorice roots. The medicines are used in cooperation for achieving the functions of nourishing yin and tonifying yang, and relieving phlegm and dampness. The clinical symptoms of patients suffering from the latent glomerulonephritis can be effectively relieved, the number of urine erythrocyte and the quantitative level of urine protein in 24 hours can be decreased, and the glomerular filtration rate can be increased.

The invention discloses a pharmaceutical compound preparation for treating glomerulonephritis. The compound preparation comprises the following components in parts by weight: 10 to 300 parts of nitrofurantoin, 10 to 120 parts of vancomycin, and 10 to 1600 parts of drug carrier. Nitrofurantoin and vancomycin are taken as the pharmaceutical components and mixed with the drug carrier to prepare the compound preparation. The compound preparation is convenient to take, is very safe, has a prominent effect, can greatly reduce complications, generates few sequelae, barely causes adverse reactions, and promotes the healing.

A treatment for glomerulonephritis, and other renal dysfunctions using a compound of Formula I is disclosed.

The invention belongs to the technical field of medicines and particularly relates to medicine composition for treating kidney yin-yang deficiency type latent glomerulonephritis. The medicine composition is prepared from traditional Chinese medicines in parts by weight as follows: 4-8 parts of Cerastium arvense L., 4-8 parts of rhizomes of largeleaf curculigo, 4-8 parts of pecteilis susannae, 4-8 parts of pleurotus ostreatus, 4-8 parts of dysosma majorensis, 4-8 parts of balanophora polyandra, 4-8 parts of aralia elata, 4-8 parts of herbs of creeping rattlesnake plantain, 4-8 parts of moutan bark, 4-8 parts of oriental waterplantain rhizomes and 4-8 parts of liquorice. The medicines are combined to perform the efficacy of benefiting qi, tonifying yang and nourishing yin and the kidney; the medicine composition can effectively reduce clinical symptoms of a patient suffering from latent glomerulonephritis, reduce the number of urine erythrocyte and the urine protein quantitation level in 24 hours and increase the glomerular filtration rate.